{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:21:34Z","timestamp":1790738494725,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10557-023-07457-w","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T07:02:12Z","timestamp":1686726132000},"page":"171-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparing Renin-Angiotensin-Aldosterone Blockade Regimens for Long-Term Chemotherapy-Related Cardiac Dysfunction: A Network Meta-Analysis"],"prefix":"10.1007","volume":"39","author":[{"given":"Jiaqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainsley Ryan Yan Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeba","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun En","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Ling","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Moiz","family":"Tyebally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda Xinwei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh Yang","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-2869","authenticated-orcid":false,"given":"Ching-Hui","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"issue":"8","key":"7457_CR1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.4065\/80.8.1087","volume":"80","author":"SM Ansell","year":"2005","unstructured":"Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005;80(8):1087\u201397.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"7457_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. Jama. 2019;321(3):288\u2013300.","journal-title":"Jama."},{"issue":"Suppl 1","key":"7457_CR3","doi-asserted-by":"publisher","first-page":"9s","DOI":"10.2967\/jnumed.115.157834","volume":"57","author":"ES McDonald","year":"2016","unstructured":"McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. J Nucl Med. 2016;57(Suppl 1):9s\u201316s.","journal-title":"J Nucl Med"},{"issue":"4","key":"7457_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214\u201320.","journal-title":"Curr Cardiol Rev"},{"issue":"3","key":"7457_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"7457_CR6","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","volume":"266","author":"LJ Steinherz","year":"1991","unstructured":"Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Jama. 1991;266(12):1672\u20137.","journal-title":"Jama"},{"key":"7457_CR7","doi-asserted-by":"crossref","unstructured":"Lee ARYB, Yau CE, Low CE, Li J, Ho RCM, Ho CSH. Severity and Longitudinal Course of Depression, Anxiety and Post-Traumatic Stress in Paediatric and Young Adult Cancer Patients: A Systematic Review and Meta-Analysis. J Clin Med. 2023 Feb 23;12(5):1784.","DOI":"10.3390\/jcm12051784"},{"key":"7457_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.genhosppsych.2023.01.008","volume":"81","author":"ARYB Lee","year":"2023","unstructured":"Lee ARYB, Leong I, Lau G, et al. Depression and anxiety in older adults with cancer: systematic review and meta-summary of risk, protective and exacerbating factors. Gen Hosp Psychiatry. 2023;81:32\u201342.","journal-title":"Gen Hosp Psychiatry"},{"issue":"8","key":"7457_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893\u2013911.","journal-title":"J Clin Oncol"},{"issue":"36","key":"7457_CR10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"27","key":"7457_CR11","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","volume":"43","author":"C Lewinter","year":"2022","unstructured":"Lewinter C, Nielsen TH, Edfors LR, et al. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur Heart J. 2022;43(27):2562\u20139.","journal-title":"Eur Heart J"},{"issue":"4","key":"7457_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1159\/000512848","volume":"146","author":"H Lin","year":"2021","unstructured":"Lin H, Liang G, Wu Y, Chen L. Protective effects of ACEI\/ARB on left ventricular function in anthracycline-induced chronic cardiotoxicity: a meta-analysis of randomized controlled trials. Cardiology. 2021;146(4):469\u201380.","journal-title":"Cardiology"},{"issue":"11","key":"7457_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"7457_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"1","key":"7457_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/XEB.0000000000000155","volume":"17","author":"Z Jordan","year":"2019","unstructured":"Jordan Z, Lockwood C, Munn Z, Aromataris E. The updated Joanna Briggs Institute Model of Evidence-Based Healthcare. Int J Evid Based Healthc. 2019;17(1):58\u201371.","journal-title":"Int J Evid Based Healthc"},{"key":"7457_CR16","doi-asserted-by":"crossref","unstructured":"B\u00e9liveau A, Boyne DJ, Slater J, Brenner D, Arora P. BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses. BMC Med Res Methodol. 2019 Oct 22;19(1):196.","DOI":"10.1186\/s12874-019-0829-2"},{"issue":"1","key":"7457_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","volume":"17","author":"M Akpek","year":"2015","unstructured":"Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"7457_CR18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol. 2016;2(8):1030\u20137.","journal-title":"JAMA Oncol"},{"issue":"3","key":"7457_CR19","doi-asserted-by":"publisher","first-page":"487.e1","DOI":"10.1016\/j.ahj.2010.05.037","volume":"160","author":"C Cadeddu","year":"2010","unstructured":"Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160(3):487.e1\u20137.","journal-title":"Am Heart J"},{"issue":"23","key":"7457_CR20","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474\u201381.","journal-title":"Circulation"},{"issue":"2","key":"7457_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaccao.2019.10.001","volume":"1","author":"MK Davis","year":"2019","unstructured":"Davis MK, Villa D, Tsang TSM, et al. Effect of eplerenone on diastolic function in women receiving anthracycline-based chemotherapy for breast cancer. JACC CardioOncol. 2019;1(2):295\u20138.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"7457_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/2193-1801-2-198","volume":"2","author":"M Dess\u00ec","year":"2013","unstructured":"Dess\u00ec M, Madeddu C, Piras A, et al. Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate. Springerplus. 2013;2(1):198.","journal-title":"Springerplus"},{"key":"7457_CR23","doi-asserted-by":"publisher","first-page":"v64","DOI":"10.1093\/annonc\/mdx362.058","volume":"28","author":"AM Elkhateeb","year":"2017","unstructured":"Elkhateeb AM, Diab DR, Ibrahim H, et al. Prevention of cardiotoxicity in breast cancer patients: a randomized prospective study. Ann Oncol. 2017;28:v64.","journal-title":"Ann Oncol"},{"issue":"11","key":"7457_CR24","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ajh.21840","volume":"85","author":"P Georgakopoulos","year":"2010","unstructured":"Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85(11):894\u20136.","journal-title":"Am J Hematol"},{"issue":"22","key":"7457_CR25","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019;73(22):2859\u201368.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"7457_CR26","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671\u201380.","journal-title":"Eur Heart J"},{"issue":"25","key":"7457_CR27","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","volume":"143","author":"SL Heck","year":"2021","unstructured":"Heck SL, Mecinaj A, Ree AH, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation. 2021;143(25):2431\u201340.","journal-title":"Circulation"},{"issue":"2","key":"7457_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","volume":"17","author":"G Janbabai","year":"2017","unstructured":"Janbabai G, Nabati M, Faghihinia M, et al. Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc Toxicol. 2017;17(2):130\u20139.","journal-title":"Cardiovasc Toxicol"},{"issue":"suppl_1","key":"7457_CR29","first-page":"A20834-A","volume":"136","author":"B Kim","year":"2017","unstructured":"Kim B, Chung W-B, Youn H-J, et al. Abstract 20834: comparative effect of candesartan and cavedilol in prevention of doxorubicin induced subclinical cardiotoxicity. Circulation. 2017;136(suppl_1):A20834-A.","journal-title":"Circulation"},{"issue":"12","key":"7457_CR30","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1002\/cam4.3956","volume":"10","author":"M Lee","year":"2021","unstructured":"Lee M, Chung WB, Lee JE, et al. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Med. 2021;10(12):3964\u201373.","journal-title":"Cancer Med"},{"issue":"10","key":"7457_CR31","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","volume":"7","author":"L Livi","year":"2021","unstructured":"Livi L, Barletta G, Martella F, et al. Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial. JAMA Oncol. 2021;7(10):1544\u20139.","journal-title":"JAMA Oncol"},{"issue":"8","key":"7457_CR32","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017;35(8):870\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7457_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.33963\/KP.15163","volume":"78","author":"A S\u0142owik","year":"2020","unstructured":"S\u0142owik A, Jagielski P, Potocki P, et al. Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study. Kardiol Pol. 2020;78(2):131\u20137.","journal-title":"Kardiol Pol"},{"issue":"9","key":"7457_CR34","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.31557\/APJCP.2021.22.9.2847","volume":"22","author":"A Wihandono","year":"2021","unstructured":"Wihandono A, Azhar Y, Abdurahman M, Hidayat S. The role of lisinopril and bisoprolol to prevent anthracycline induced cardiotoxicity in locally advanced breast cancer patients. Asian Pac J Cancer Prev. 2021;22(9):2847\u201353.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"23","key":"7457_CR35","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"7457_CR36","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","volume":"7","author":"L Livi","year":"2021","unstructured":"Livi L, Barletta G, Martella F, et al. Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy. JAMA Oncology. 2021;7(10):1544.","journal-title":"JAMA Oncology"},{"issue":"4","key":"7457_CR37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77(4):392\u2013401.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"7457_CR38","doi-asserted-by":"publisher","first-page":"e018802","DOI":"10.1161\/JAHA.120.018802","volume":"10","author":"P Jeyaprakash","year":"2021","unstructured":"Jeyaprakash P, Sangha S, Ellenberger K, et al. Cardiotoxic effect of modern anthracycline dosing on left ventricular ejection fraction: a systematic review and meta-analysis of placebo arms from randomized controlled trials. J Am Heart Assoc. 2021;10(6):e018802.","journal-title":"J Am Heart Assoc"},{"key":"7457_CR39","doi-asserted-by":"crossref","unstructured":"Lee AR, Yau CE, Low CE, et al. Natural progression of left ventricular function following anthracyclines without cardioprotective therapy: a systematic review and meta-analysis. Cancers. 2023;15(2):512.","DOI":"10.3390\/cancers15020512"},{"issue":"41","key":"7457_CR40","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"key":"7457_CR41","doi-asserted-by":"publisher","first-page":"104577","DOI":"10.1016\/j.phrs.2019.104577","volume":"151","author":"X Li","year":"2020","unstructured":"Li X, Li Y, Zhang T, et al. Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials. Pharmacol Res. 2020;151:104577.","journal-title":"Pharmacol Res"},{"key":"7457_CR42","doi-asserted-by":"crossref","unstructured":"Mir A, Badi Y, Bugazia S, et al. Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis. Cardiooncology. 2023 Feb 18;9(1):10.","DOI":"10.1186\/s40959-023-00159-0"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07457-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07457-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07457-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T09:18:38Z","timestamp":1738833518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07457-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7457"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07457-w","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"assertion":[{"value":"19 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as no human and animal subjects or data were used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}